FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 26, 2026
Rein Therapeutics, Inc. (RNTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $49.9 million.
Revenue (TTM)
$0
Net income (TTM)
$-49.76M
+15.9% vs year-ago TTM
Operating cash flow (TTM)
$-18.83M
+11.3% vs year-ago TTM
Free cash flow
$-23.91M
-16.7% vs prior year
EPS (TTM)
$-1.30
+50.8% vs year-ago TTM
Dividend per share (TTM)
$0.00
Shares outstanding
28.04M
+27.5% vs prior year
Net cash
$17.29M
FY 2023
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNTX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420565
- Former names
- Aileron Therapeutics, Inc. (until Dec 9, 2024); AILERON THERAPEUTICS INC (until Mar 29, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$50.6M | -$65.1M | -$16.3M | -$27.6M | -$26.6M |
| Net income | -$49.9M | -$62.9M | -$15.7M | -$27.3M | -$26.2M |
| Diluted EPS | -$1.96 | -$3.51 | -$3.42 | -$6.02 | — |
| Operating cash flow | -$19.4M | -$22.3M | -$19.8M | -$24.9M | -$23.8M |
| Free cash flow | — | — | — | — | -$23.9M |
| Total assets | $24.2M | $62.2M | $106.0M | $22.0M | $48.5M |
| Total liabilities | $7.2M | $7.8M | $7.7M | $3.4M | $4.6M |
| Stockholders' equity | $16.9M | $54.4M | $98.3M | $18.6M | $43.9M |
| Cash and investments | $3.2M | $12.9M | $17.3M | $21.2M | $45.9M |
| Total debt | — | — | $48,000 | $48,000 | $162,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 4, 2026 | Sep 4, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 27, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 21, 2026 | Jul 20, 2026 |
| ARS | Annual report to shareholders | Jun 8, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 525 Rein Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.